DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Vedolizumab SC

First Posted Date: 2019-05-23

Last Posted Date: 2019-11-13

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT03961295

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Vedolizumab SC

First Posted Date: 2019-05-23

Last Posted Date: 2019-11-14

Lead Sponsor: Takeda

Target Recruit Count: 204

Registration Number: NCT03961308

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Vedolizumab SC

First Posted Date: 2019-05-14

Last Posted Date: 2019-11-13

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT03949621

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Vedolizumab SC

First Posted Date: 2019-05-14

Last Posted Date: 2022-07-29

Lead Sponsor: Takeda

Target Recruit Count: 102

Registration Number: NCT03948581

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery

Phase 2

Terminated

Conditions: Crohn Disease

Interventions: Drug: TAK-018 Placebo
Drug: TAK-018

First Posted Date: 2019-05-09

Last Posted Date: 2023-09-07

Lead Sponsor: Takeda

Target Recruit Count: 34

Registration Number: NCT03943446

Locations: 🇫🇷
Hopital Saint-Louis, Paris Cedex 10, Il-de-France, France
🇫🇷
Centre Hospitalier Universitaire de Nice Hopital l'Archet, Nice Cedex 3, Provence Alpes Cote D'Azur, France
🇺🇸
University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States

and more 38 locations

A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation

Completed

Conditions: Hodgkin Disease
Lymphoma, Large-cell, Anaplastic

First Posted Date: 2019-05-08

Last Posted Date: 2024-07-15

Lead Sponsor: Takeda

Target Recruit Count: 2000

Registration Number: NCT03942263

Locations: 🇷🇺
State Budget Public Health Institution "Regional Oncological Dispensary", Irkutsk, Russian Federation
🇷🇺
The State Budgetary Institution of Healthcare "Regional Oncologic Dispensary", Penza, Russian Federation
🇷🇺
Kaluga Regional Clinical Oncologic Dispensary, Kaluga, Russian Federation

and more 47 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: TAK-994
Drug: TAK-994 Placebo

First Posted Date: 2019-05-01

Last Posted Date: 2020-06-24

Lead Sponsor: Takeda

Target Recruit Count: 121

Registration Number: NCT03933488

Locations: 🇺🇸
Parexel International, Glendale, California, United States
🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

Phase 2

Completed

Conditions: Postoperative Gastrointestinal Dysfunction

Interventions: Drug: TAK-954 Placebo
Drug: TAK-954

First Posted Date: 2019-02-01

Last Posted Date: 2023-06-23

Lead Sponsor: Takeda

Target Recruit Count: 209

Registration Number: NCT03827655

Locations: 🇩🇪
Universitatsklinikum Freiburg, Freiburg, Baden-wuerttemberg, Germany
🇩🇪
Sankt Josef-Hospital, Bochum, Nordrhein-westfalen, Germany
🇩🇪
Universitatsklinikum Mannheim, Mannheim, Baden-wuerttemberg, Germany

and more 22 locations

Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Vedolizumab

First Posted Date: 2019-01-31

Last Posted Date: 2025-02-19

Lead Sponsor: Takeda

Target Recruit Count: 1096

Registration Number: NCT03824561

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

Post Marketing Surveillance Study for ADYNOVATE in South Korea

Completed

Conditions: Hemophilia A

Interventions: Biological: ADYNOVATE

First Posted Date: 2019-01-31

Last Posted Date: 2024-02-26

Lead Sponsor: Takeda

Target Recruit Count: 341

Registration Number: NCT03824522

Locations: 🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷
Daegu Catholic University Medical Center, Daegu, Korea, Republic of
🇰🇷
Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy